๐Ÿ”ฌDeep Research

DVA โ€” DaVita ยท catalysts, narrative & risks

ยท22 sourcesDVA forecast โ†’

Point-in-time snapshot (as of ~Nov 15, 2026)

DVA last traded near $174.56 (up ~0.3% on Nov 14), with a market capitalization near $10.9โ€“11.0 billion, a 52-week range of roughly $101โ€“$247, and a trailing P/E near 13 [12], [16]. Berkshire Hathaway remains the largest owner at ~41.2% of shares [22], [10]. DaVita is a comprehensive kidney-care provider operating dialysis centers and lab services; as of Sept 30, 2026 it served ~298,100 patients at ~3,269 outpatient centers (2,671 in the U.S., 598 abroad) [23]. Roughly 68% of 2025 revenue came from Medicare/government programs, while commercial payers (~32% of revenue) generate nearly all of the profit [22].

Recent catalysts (last ~1โ€“3 months)


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’